Literature DB >> 19273674

GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.

Matthew F McCown1, Sonal Rajyaguru, Simran Kular, Nick Cammack, Isabel Nájera.   

Abstract

In vitro, telaprevir selects subtype-specific resistance pathways for hepatitis C virus GT-1a and GT-1b, as described to have occurred in patients. In GT-1a, the HCV-796 resistance mutation C316Y has low replication capacity (7%) that can be compensated for by the emergence of the mutation L392F or M414T, resulting in an increase in replication levels of > or = 10-fold.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19273674      PMCID： PMC2681573          DOI： 10.1128/AAC.01598-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

Authors:  A U Neumann; N P Lam; H Dahari; M Davidian; T E Wiley; B P Mika; A S Perelson; T J Layden
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

2.  In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.

Authors:  Sophie Le Pogam; Wen-Rong Jiang; Vincent Leveque; Sonal Rajyaguru; Han Ma; Hyunsoon Kang; Sharon Jiang; Margaret Singer; Samir Ali; Klaus Klumpp; Dave Smith; Julian Symons; Nick Cammack; Isabel Nájera
Journal:  Virology       Date:  2006-05-19       Impact factor: 3.616

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors:  Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

5.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

6.  Replication studies using genotype 1a subgenomic hepatitis C virus replicons.

Authors:  Baohua Gu; Adam T Gates; Olaf Isken; Sven-Erik Behrens; Robert T Sarisky
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.

Authors:  Klaus Klumpp; Vincent Lévêque; Sophie Le Pogam; Han Ma; Wen-Rong Jiang; Hyunsoon Kang; Caroline Granycome; Margaret Singer; Carl Laxton; Julie Qi Hang; Keshab Sarma; David B Smith; Dieter Heindl; Chris J Hobbs; John H Merrett; Julian Symons; Nick Cammack; Joseph A Martin; Rene Devos; Isabel Nájera
Journal:  J Biol Chem       Date:  2005-11-29       Impact factor: 5.157

9.  The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.

Authors:  Matthew F McCown; Sonal Rajyaguru; Sophie Le Pogam; Samir Ali; Wen-Rong Jiang; Hyunsoon Kang; Julian Symons; Nick Cammack; Isabel Najera
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

10.  Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Authors:  Anita Y M Howe; Huiming Cheng; Stephen Johann; Stanley Mullen; Srinivas K Chunduru; Dorothy C Young; Joel Bard; Rajiv Chopra; Girija Krishnamurthy; Tarek Mansour; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191
View more
  43 in total

Review 1.  Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Authors:  Maya Gambarin-Gelwan; Ira M Jacobson
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

Authors:  Lisette Lagacé; Peter W White; Christiane Bousquet; Nathalie Dansereau; Florence Dô; Montse Llinas-Brunet; Martin Marquis; Marie-Josée Massariol; Roger Maurice; Catherine Spickler; Diane Thibeault; Ibtissem Triki; Songping Zhao; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

3.  Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Veronique Zennou; Meg Keilman; Yuao Zhu; Shuiyun Lan; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

4.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

5.  Hepatitis: HCV variability, the immune system and resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07       Impact factor: 46.802

6.  Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.

Authors:  Margaret Robinson; Yang Tian; William E Delaney; Andrew E Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-06       Impact factor: 11.205

7.  Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.

Authors:  Nadejda Valiaeva; David L Wyles; Robert T Schooley; Julia B Hwu; James R Beadle; Mark N Prichard; Karl Y Hostetler
Journal:  Bioorg Med Chem       Date:  2011-06-13       Impact factor: 3.641

8.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Authors:  Evguenia S Svarovskaia; Hadas Dvory-Sobol; Neil Parkin; Christy Hebner; Viktoria Gontcharova; Ross Martin; Wen Ouyang; Bin Han; Simin Xu; Karin Ku; Sophia Chiu; Edward Gane; Ira M Jacobson; David R Nelson; Eric Lawitz; David L Wyles; Neby Bekele; Diana Brainard; William T Symonds; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Clin Infect Dis       Date:  2014-09-28       Impact factor: 9.079

9.  Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.

Authors:  Sylvie Larrat; Jean-Dominique Poveda; Camille Coudret; Katia Fusillier; Nelly Magnat; Anne Signori-Schmuck; Vincent Thibault; Patrice Morand
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

10.  Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.